Physician profile
Joel Lilly
NPI 1104899137
$3,459.97
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,203 · 2020: $147 · 2021: $110.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,516.57 | 2019 | |
| Boston Scientific Corporation | $306.36 | 2019 | |
| Myovant Sciences INC. | $110.05 | 2021 | |
| Astellas Pharma US INC | $94.89 | 2019-2020 | |
| Coloplast Corp | $80.31 | 2019-2020 | |
| Endo Pharmaceuticals INC. | $77.99 | 2019-2020 | |
| C. R. Bard, INC. & Subsidiaries | $49.40 | 2019 | |
| Ferring Pharmaceuticals INC. | $46.87 | 2019 | |
| Rochester Medical Corporation | $35.44 | 2020 | |
| Janssen Biotech, INC. | $34.65 | 2019 | |
| 180 Medical, INC. | $28.02 | 2019 | |
| Convatec INC. | $26.90 | 2019 | |
| Travere Therapeutics, INC. | $23.11 | 2019-2020 | |
| Kaleo, INC. | $17.55 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $11.86 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Lilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.